Status:
UNKNOWN
Prospective Study on the Risks of Dengue Fever for the Fetus.
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Conditions:
Dengue Fever
Eligibility:
FEMALE
18+ years
Brief Summary
Dengue is the most common arbovirus worldwide (390 million people infected each year) and belongs to the Flavivirus genus of the Flaviviridae family like Zika. Its expansion has been rapid since the l...
Eligibility Criteria
Inclusion
- Pregnant patients
- Major
- Affiliated with social security
- Symptomatic or pauci-symptomatic dengue
- Biological confirmation of dengue fever by dengue positive PCR or IgM positive during the current dengue episode
Exclusion
- Multiple pregnancy
- Patient's refusal
- Protected persons: person deprived of liberty by judicial or administrative decision, minor, and person subject to a legal protection measure: guardianship or curators)
Key Trial Info
Start Date :
March 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04822441
Start Date
March 19 2021
End Date
March 1 2023
Last Update
November 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de la Réunion
Saint-Pierre, France, 97448